(VIANEWS) – Moderna (MRNA), Clean Harbors (CLH), Vivaldi Asset Management, LLC (ADC) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Moderna (MRNA)

1202.8% sales growth and 72.43% return on equity

Moderna’s sales growth this year is expected to be 2434.2% and a negative 2.5% for next year.

Year-on-year quarterly revenue growth grew by 6398.5%, now sitting on 7.02B for the twelve trailing months.

Volume

Today’s last reported volume for Moderna is 5200590 which is 52.01% below its average volume of 10837900.

Moderna’s sales growth for the next quarter is 1202.8%. The company’s growth estimates for the current quarter and the next is 1694.9% and 1681.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72.43%.

Volatility

Moderna’s last day, last week, and last month’s current intraday variation average was 0.43%, 1.75%, and 3.58%, respectively.

Moderna’s highest amplitude of average volatility was 7.12% (day), 6.52% (last week), and 7.50% (last month), respectively.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $145.74 at 00:22 EST, way under its 52-week high of $497.49 and way higher than its 52-week low of $102.66.

Moderna’s Moving Average

Moderna’s value is way under its 50-day moving average of $298.96 and way under its 200-day moving average of $267.83.

Previous days news about Moderna(MRNA)

  • According to Bloomberg Quint on Tuesday, 15 February, "It found that infants were 61% less likely to require hospitalization from Covid-19 if their mother had received two doses of Pfizer Inc. or Moderna Inc.’s vaccines."
  • According to Bloomberg Quint on Wednesday, 16 February, "While BioNTech, Moderna Inc. and other companies are pursuing their own vaccine projects in Africa, health advocates have urged them instead to support a World Health Organization mRNA initiative that’s already underway in South Africa. "
  • This reopening stock has A better 1-year return than Moderna, Pfizer, biontech, Novavax and vaxart. According to Benzinga on Thursday, 17 February, "Since February 2021, Macy’s stock’s one-year return has outperformed several of the world’s most popular vaccine stocks: Moderna Inc (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), BioNTech SE - ADR (NASDAQ:BNTX), Novavax, Inc. (NASDAQ:NVAX) and Vaxart Inc (NASDAQ:VXRT)."
  • According to Bloomberg Quint on Tuesday, 15 February, "The firm is the largest investor in vaccine producer Moderna Inc. and biotech company Illumina Inc., and its funds are a top-10 shareholder in Zoom Video Communications Inc., e-commerce firm Shopify Inc. and Netflix Inc., according to data compiled by Bloomberg. "
  • According to The New York Times on Tuesday, 15 February, "Tyson defines fully vaccinated as two doses of the Pfizer-BioNTech or Moderna shots or one dose of the Johnson & Johnson shot, Mr. Brower said Tuesday. "

2. Clean Harbors (CLH)

29.9% sales growth and 13.99% return on equity

Clean Harbors, Inc. provides environmental and industrial services in North America.

Clean Harbors’s sales growth this year is anticipated to be 18.1% and 19.9% for next year.

Year-on-year quarterly revenue growth grew by 22.1%, now sitting on 3.48B for the twelve trailing months.

Volume

Today’s last reported volume for Clean Harbors is 135482 which is 59.93% below its average volume of 338162.

Clean Harbors’s sales growth for the next quarter is 29.9%. The company’s growth estimates for the present quarter and the next is 7.9% and 73.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.99%.

Volatility

Clean Harbors’s last day, last week, and last month’s current intraday variation average was 0.04%, 1.00%, and 1.30%, respectively.

Clean Harbors’s highest amplitude of average volatility was 2.14% (day), 2.40% (last week), and 3.07% (last month), respectively.

Clean Harbors’s Stock Yearly Top and Bottom Value

Clean Harbors’s stock is valued at $91.19 at 00:22 EST, way below its 52-week high of $118.89 and way higher than its 52-week low of $81.30.

Clean Harbors’s Moving Average

Clean Harbors’s worth is under its 50-day moving average of $97.31 and under its 200-day moving average of $98.63.

3. Vivaldi Asset Management, LLC (ADC)

24.6% sales growth and 4.04% return on equity

Vivaldi Asset Management, LLC’s sales growth this year is anticipated to be 35.5% and 23.5% for next year.

Year-on-year quarterly revenue growth grew by 37.2%, now sitting on 319.33M for the twelve trailing months.

Volume

Today’s last reported volume for Vivaldi Asset Management, LLC is 138360 which is 75.51% below its average volume of 565175.

Vivaldi Asset Management, LLC’s sales growth for the next quarter is 24.6%. The company’s growth estimates for the present quarter and the next is 11.9% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.04%.

Volatility

Vivaldi Asset Management, LLC’s last day, last week, and last month’s current intraday variation average was 0.02%, 1.41%, and 1.16%, respectively.

Vivaldi Asset Management, LLC’s highest amplitude of average volatility was 1.00% (day), 2.51% (last week), and 2.24% (last month), respectively.

Vivaldi Asset Management, LLC’s Stock Yearly Top and Bottom Value

Vivaldi Asset Management, LLC’s stock is valued at $63.43 at 00:22 EST, way under its 52-week high of $75.95 and above its 52-week low of $61.27.

Vivaldi Asset Management, LLC’s Moving Average

Vivaldi Asset Management, LLC’s worth is under its 50-day moving average of $67.88 and under its 200-day moving average of $70.43.

4. Antares Pharma (ATRS)

17.4% sales growth and 63.08% return on equity

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.

Antares Pharma’s sales growth this year is expected to be 22.1% and 23.2% for next year.

Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 179.38M for the twelve trailing months.

Volume

Today’s last reported volume for Antares Pharma is 1352880 which is 99.55% above its average volume of 677939.

Antares Pharma’s sales growth for the next quarter is 17.4%. The company’s growth estimates for the present quarter and the next is a negative 66.7% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 63.08%.

Volatility

Antares Pharma’s last day, last week, and last month’s current intraday variation average was 0.84%, 1.62%, and 1.95%, respectively.

Antares Pharma’s highest amplitude of average volatility was 1.96% (day), 2.80% (last week), and 3.46% (last month), respectively.

Antares Pharma’s Stock Yearly Top and Bottom Value

Antares Pharma’s stock is valued at $3.62 at 00:22 EST, way under its 52-week high of $5.07 and way above its 52-week low of $3.11.

Antares Pharma’s Moving Average

Antares Pharma’s worth is higher than its 50-day moving average of $3.39 and below its 200-day moving average of $3.80.

5. California BanCorp (CALB)

8% sales growth and 9.31% return on equity

California BanCorp operates as the bank holding company for California Bank of Commerce that provides commercial banking services to small to medium-sized businesses and professional firms in California.

California BanCorp’s sales growth this year is anticipated to be 10% and 15.1% for next year.

Year-on-year quarterly revenue growth grew by 11.4%, now sitting on 58.9M for the twelve trailing months.

Volume

Today’s last reported volume for California BanCorp is 801 which is 88.62% below its average volume of 7039.

California BanCorp’s sales growth for the next quarter is 8%. The company’s growth estimates for the ongoing quarter and the next is 23.5% and negative -18%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.31%.

California BanCorp’s Stock Yearly Top and Bottom Value

California BanCorp’s stock is valued at $21.70 at 00:22 EST, under its 52-week high of $24.00 and way higher than its 52-week low of $14.12.

California BanCorp’s Moving Average

California BanCorp’s value is higher than its 50-day moving average of $20.55 and way higher than its 200-day moving average of $18.65.

6. FormFactor (FORM)

6.8% sales growth and 10.3% return on equity

FormFactor, Inc. designs, manufactures, and sells probe cards, analytical probes, probe stations, metrology systems, thermal systems, and cryogenic systems to semiconductor companies and scientific institutions.

FormFactor’s sales growth this year is anticipated to be 10% and 7.1% for next year.

Year-on-year quarterly revenue growth grew by 6.7%, now sitting on 761.72M for the twelve trailing months.

Volume

Today’s last reported volume for FormFactor is 379825 which is 4.39% above its average volume of 363829.

FormFactor’s sales growth for the next quarter is 6.8%. The company’s growth estimates for the ongoing quarter and the next is a negative 6.8% and 5.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.3%.

Volatility

FormFactor’s last day, last week, and last month’s current intraday variation average was 3.87%, 2.28%, and 2.83%, respectively.

FormFactor’s highest amplitude of average volatility was 4.58% (day), 4.03% (last week), and 5.49% (last month), respectively.

FormFactor’s Stock Yearly Top and Bottom Value

FormFactor’s stock is valued at $40.00 at 00:22 EST, way under its 52-week high of $52.39 and way above its 52-week low of $32.69.

FormFactor’s Moving Average

FormFactor’s worth is under its 50-day moving average of $42.78 and higher than its 200-day moving average of $38.69.